Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1431-1438 , November 2009

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia

  • Paul M. Armistead

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Paul Armistead, MD, PhD, Lineberger Comprehensive Cancer Center, 21-244, University of North Carolina, 450 West Road, Chapel Hill, NC 27599.
    • ,
  • Marcos de Lima

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Sherry Pierce

      Affiliations

    • Department of Leukemia, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Wei Qiao

      Affiliations

    • Department of Biostatistics, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Xuemei Wang

      Affiliations

    • Department of Biostatistics, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Peter F. Thall

      Affiliations

    • Department of Biostatistics, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Farhad Ravandi

      Affiliations

    • Department of Leukemia, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Hagop Kantarjian

      Affiliations

    • Department of Leukemia, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Richard Champlin

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, M.D. Anderson Cancer Center, Houston Texas
    • ,
  • Elihu Estey

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington

Received 27 May 2009 ,Accepted 9 July 2009.

References 

  1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907
  2. Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer. 2007;
  3. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969–1978
  4. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced-stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–1163
  5. Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–114
  6. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476–479
  7. Randles R, Wolfe D. Introduction to the Theory of Nonparametric Statistics. New York: Wiley; 1979;1
  8. Fisher R. On the interpretation of χ2 from contingency tables, and the calculation of p. J R Stat Soc. 1922;85:87–94
  9. Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163–170
  11. Jennison C, Turnbull B. Group-Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2000;
  12. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  13. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113:1631–1638
  14. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14:282–289

 Financial disclosure: See Acknowledgments on page 1437.

PII: S1083-8791(09)00338-3

doi: 10.1016/j.bbmt.2009.07.008

Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1431-1438 , November 2009

Article Tools

* Image Usage & Resolution